Minims Lidocaine Hydrochloride 4% w/v & Fluorescein Sodium 0.25% w/v Eye Drops, solution

Pajjiż: Irlanda

Lingwa: Ingliż

Sors: HPRA (Health Products Regulatory Authority)

Ingredjent attiv:

Lignocaine hydrochloride; Fluorescein sodium

Disponibbli minn:

Bausch & Lomb UK Limited

Kodiċi ATC:

S01JA; S01JA51

INN (Isem Internazzjonali):

Lignocaine hydrochloride; Fluorescein sodium

Dożaġġ:

4.0/0.25 % percent weight/volume

Għamla farmaċewtika:

Eye drops, solution

Tip ta 'preskrizzjoni:

Product subject to prescription which may not be renewed (A)

Żona terapewtika:

Colouring agents; fluorescein, combinations

L-istatus ta 'awtorizzazzjoni:

Marketed

Data ta 'l-awtorizzazzjoni:

1983-03-24

Karatteristiċi tal-prodott

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Minims Lidocaine Hydrochloride 4% w/v & Fluorescein Sodium 0.25% w/v
Eye Drops, solution
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Lidocaine Hydrochloride 4 % w/v and Fluorescein Sodium 0.25 % w/v
_For a full list of excipients, see section 6.1_
3 PHARMACEUTICAL FORM
Eye drops, solution (eye drops)
Single use, sterile, clear, slightly yellow, slightly viscous eye
drops, solution.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
As a diagnostic stain and local anaesthetic combined.
Minims Lidocaine & Fluorescein can be used in the measurement
of intraocular pressure by Goldmann tonometry.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
_Adults (including the elderly):_
One to two drops, as required.
_Children:_
As directed by the physician.
4.3 CONTRAINDICATIONS
Do not use in patients with a known hypersensitivity to either of the
active ingredients.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Use with caution on an inflamed eye, as hyperaemia greatly increases
the rate of systemic absorption through the
conjunctiva.
The cornea may be damaged by prolonged application of anaesthetic eye
drops.
The anaesthetised eye should be protected from dust and contamination.
Systemic absorption may be minimised by compressing the lacrimal sac
at the medial canthus for one minute during and
after the instillation of the drops.
This blocks the passage of the drops via the naso lacrimal duct to the
wide absorptive
area of the nasal and pharyngeal mucosa.
It is especially advisable in children.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___